Publikace |
2022
Abstrakt
These new results provide further evidence for the possible disease modifying capability of ropeginterferon alfa-2b, which may alter the natural course of PV. In a sizable proportion of ropeginterferon alfa-2b-treated patients, treatment discontinuation (a goal that cannot be achieved in PV with any other currently available therapy) could potentially be considered, and warrants further study.
